Medical News / Directly from ASH Meeting 2020, Jeffrey Wolf, MD: Optimizing Multiple Myeloma Assessment

The modes of multiple myeloma assessment and screening has progressed over decades in near-alignment with the advancement of therapy for the rare disease. Though neither observation nor treatment for patients with multiple myeloma have yet been optimized, new data presented at the American Society of Hematology (ASH) 2020 Annual Meeting this weekend showed a more refined method of treatment decision-making. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

MORE MEDICAL NEWS
A new study presented at the American Society of Hematology (ASH) 2020 Annual Meeting this weekend ... read more
A mobile health (mHealth) app may help children manage pain and symptoms related to sickle cell ... read more
Cognitive and emotional functions in pediatric patients should not be overlooked when assessing potential for sickle ... read more
There is a high false-negative rate of coronavirus disease 2019 (COVID-19) in patients with hematological malignancies, ... read more